TEVA-LENOLTEC NO. 3 300 MG
ACETAMINOPHEN : 300 MG CODEINE PHOSPHATE : 30 MG CAFFEINE : 15 MG · DIN 00653276 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-LENOLTEC NO. 3?
TEVA-LENOLTEC NO. 3 300 MG contains ACETAMINOPHEN : 300 MG CODEINE PHOSPHATE : 30 MG CAFFEINE : 15 MG. It is listed in the Health Canada Drug Product Database under DIN 00653276, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-LENOLTEC NO. 3 used for?
TEVA - LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00653276 |
|---|---|
| Brand name | TEVA-LENOLTEC NO. 3 |
| Generic / active ingredient | ACETAMINOPHEN : 300 MG CODEINE PHOSPHATE : 30 MG CAFFEINE : 15 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AJ06 CODEINE AND PARACETAMOL |
| AHFS class | 28:08.08 ; 28:08.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Oct-2018 |
| Original market date | 1985-12-31 00:00:00 |
How is it administered?
Adults: Short-term relief of mild to moderate pain. Tablets must be swallowed whole. Use lowest effective dose for shortest period. Do not use for pain >5 days or fever >3 days without medical review.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
null
Contraindications
Children <12; pediatric tonsillectomy/adenoidectomy; CYP2D6 ultra-rapid metabolizers; severe hepatic/renal impairment; acute asthma/respiratory depression; GI obstruction; MAOIs use within 14 days.
Warnings and precautions
Serious risks of addiction, abuse, misuse, and fatal respiratory depression. Risk of death in CYP2D6 ultra-rapid metabolizers. Avoid alcohol. Risk of NOWS if used during pregnancy.
Is CODEINE AND PARACETAMOL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by PURDUE PHARMA, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02AJ06 CODEINE AND PARACETAMOL. 9 of 66 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACETAMINOPHEN WITH CODEINE - CAPLET | 300 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02143933 |
| ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE TABLETS | 300 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 02154234 |
| PMS-ACETAMINOPHEN WITH CODEINE ELIXIR | 8 MG / 5 ML | ELIXIR | PHARMASCIENCE INC | MARKETED | DIN 00816027 |
| TEVA-EMTEC-30 | 30 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00608882 |
| TEVA-LENOLTEC NO. 1 | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00653233 |
| TEVA-LENOLTEC NO. 2 | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00653241 |
| TEVA-LENOLTEC NO. 4 | 60 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00621463 |
| TRIATEC-30 | 300 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 00789828 |
| (EXTRA STRENGTH) ACETAMINOPHEN, CAFFEINE & 8MG CODEINE PHOSPHATE CAPLETS | 15 MG | TABLET | STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | CANCELLED POST MARKET | DIN 02236871 |
| ACET 2 | 15 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00706515 |
Who else supplies CODEINE AND PARACETAMOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CODEINE AND PARACETAMOL appears in 25 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.